Review explores the complex interplay between gut microbiota dysregulation in obesity and its impacts on white and brown adipose tissue metabolism, focusing on direct and indirect effects on mitochondria, highlighting potential avenues for obesity treatment through microbiota-focused strategies.
Iovance looks to advance its non-small cell lung cancer therapy – Pharmaceutical Technology
Lifileucel received a biologics license application (BLA) in May 2023, with a Prescription Drug User Fee Act (PDUFA) target action date set for 25 November